New Weapons Against HIV

As the AIDS pandemic enters its third decade, viral resistance is beginning to counter the success of "highly active antiretroviral treatment" (HAART), the multidrug cocktails introduced in 1996. "Viral resistance is a significant problem, particularly for patients who began therapy in the pre-protease inhibitor era and who developed resistance to multiple reverse transcriptase inhibitors," says Robert Schooley, a professor of infectious diseases at the University of Colorado Health Sciences Cen

| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

According to the World Health Organization, at least 42 million people worldwide are HIV positive, and each day, 16,000 more become infected. Viral resistance, an inevitability of molecular evolution, arises when treatments do not totally suppress replication, so that variants can flourish. "HIV so far has been able to resist anything. There are so many viral variants that the chance that one can overcome a specific inhibition is certainly there," explains Dani Bolognesi, chief executive officer of Trimeris Corp. of Durham, N.C. "We now combine a number of different inhibitors that operate under different mechanisms so the chance that HIV replicates and spawns a variant that is resistant to all are low,"

A mathematical model based on the rate of increase of drug-resistant HIV infections in San Francisco predicts that by 2005, 42 percent of the city's cases will be resistant.1 The study also revealed that resistance arises more often ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Ricki Lewis

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo